Termination of Material Agreement (Form 8-K)

Item 1.02. Termination of a Material Definitive Agreement.

As previously disclosed, on July 2, 2020, Matinas BioPharma Holdings, Inc. (the "Company") entered into an At-The-Market Sales Agreement (the "Sales Agreement") with BTIG, LLC ("BTIG"), pursuant to which the Company could offer and sell shares of its common stock, par value $0.0001 per share ("Common Stock"), having an aggregate offering price of up to $50,000,000, from time to time through BTIG in "at-the-market offerings" as defined in Rule 415 of the Securities Act of 1933, as amended.

On July 23, 2026, pursuant to and in accordance with Section 12(a) of the Sales Agreement, BTIG notified the Company that BTIG is terminating the Sales Agreement, effective immediately. The Company is not subject to any termination penalties or other expenses related to the termination of the Sales Agreement.

The description of the Sales Agreement contained in this Current Report on Form 8-K does not purport to be complete and is qualified in its entirety by reference to the copy of the Sales Agreement filed as Exhibit 1.01 to the Current Report on Form 8-K filed with the Securities and Exchange Commission on July 2, 2020.